Michael Ehlers is bet­ting $40M that an AI out­fit has fig­ured out how to beat the block­buster IL-2 chal­lenge

Sanofi was so in­trigued by the prospect of fig­ur­ing out a break­through on IL-2 in can­cer that Paul Hud­son re­cent­ly en­gi­neered a $2.5 bil­lion ac­qui­si­tion of Syn­thorx to add it to the pipeline. Now Michael Ehlers be­lieves he’s found the key to the IL-2 chal­lenge, and he’s steer­ing a straight course in­to a hu­man study — at a much low­er price.

This morn­ing the ex-Bio­gen R&D chief and cur­rent CSO at ATP (what had been Ap­ple Tree Part­ners) un­veiled a deal to part­ner with Bi­olo­jic De­sign on an an­ti­body their com­pu­ta­tion­al de­sign team came up with that binds di­rect­ly to nat­u­ral­ly oc­cur­ring IL-2 and drags it to low affin­i­ty ef­fec­tor T cells and away from the Treg crowd of bad ac­tors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER